Chawla Lakhmir S
Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, Washington DC, USA.
Contrib Nephrol. 2011;174:182-190. doi: 10.1159/000329396. Epub 2011 Sep 9.
Acute kidney injury (AKI) has been shown to be associated with progression to chronic kidney disease (CKD). Multiple studies have shown that subsets of AKI survivors are at high risk for progression to advanced stage CKD and death. Risk factors associated with AKI survivors progressing to CKD have been identified and include advanced age, diabetes mellitus, decreased baseline glomerular filtration rate, severity of AKI and a low concentration of serum albumin. These risk factors can be utilized to identify those patients at highest risk for progression. Because progression to CKD in these AKI survivors typically occurs months after the initial AKI insult, a common injury pathway of CKD progression is probable, and therapeutic interventions that have been shown to retard CKD progression are likely to be effective in patients who survive AKI and then progress to CKD. AKI has many negative impacts across the spectrum of the disease. The 30-day mortality for patients with AKI is high, hence the preference to target AKI during the initiation phase. However, this phase is the most difficult point to treat AKI. The maintenance phase of AKI is longer in duration in comparison to the initiation phase, and thus the logistics are more amenable to study. However, the mainstay of treatment for the maintenance phase of AKI (renal replacement therapy) has been tested extensively and increasing the dose of renal replacement therapy has not been shown to improve outcome. Therefore, the recovery phase of AKI may represent the best opportunity to intervene in the negative outcomes of AKI.
急性肾损伤(AKI)已被证明与进展为慢性肾脏病(CKD)有关。多项研究表明,AKI幸存者的亚组进展为晚期CKD和死亡的风险很高。已确定与AKI幸存者进展为CKD相关的危险因素,包括高龄、糖尿病、基线肾小球滤过率降低、AKI的严重程度和血清白蛋白浓度低。这些危险因素可用于识别那些进展风险最高的患者。由于这些AKI幸存者进展为CKD通常发生在最初的AKI损伤数月后,CKD进展可能存在共同的损伤途径,并且已证明可延缓CKD进展的治疗干预措施可能对AKI存活后进展为CKD的患者有效。AKI在整个疾病范围内有许多负面影响。AKI患者的30天死亡率很高,因此倾向于在起始阶段针对AKI进行治疗。然而,这个阶段是治疗AKI最困难的点。与起始阶段相比,AKI的维持阶段持续时间更长,因此在后勤方面更适合进行研究。然而,AKI维持阶段的主要治疗方法(肾脏替代治疗)已得到广泛测试,增加肾脏替代治疗的剂量并未显示能改善预后。因此,AKI的恢复阶段可能是干预AKI负面结果的最佳时机。